IGC Pharma, Inc. (IGC) Form 8-K — Jun 8, 2026
IGC Pharma, Inc. entered into an amendment on June 5, 2026, to extend its existing Master Loan and Security Agreement with O-Bank Co., Ltd. The extension maintains the facility's maximum aggregate limit of $12,000,000, ensuring continued access to credit for the company. The material terms of the facility remain substantially unchanged from the previous 2025 agreement, with the exception of a slight increase in the facility fee.
Key figures
- Debt Amount
- 12000000
- Facility fee 2025
- 48000
- Facility fee 2026
- 60000
Price after filing
1 day: -4.7%7 days: -6.2%30 days: -7.0%
Close on the filing date to close N calendar days later (from $0.30). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.